Tandem Diabetes Care (TNDM) Cost of Revenue (2013 - 2026)

Tandem Diabetes Care (TNDM) has reported Cost of Revenue for 14 consecutive years, with $109.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cost of Revenue fell 4.39% year-over-year to $109.8 million; the trailing twelve-month figure through Jun 2026 stood at $458.1 million (down 3.63% YoY), and the FY2025 full-year result was $468.7 million, up 4.02% from the prior year.
• Cost of Revenue retreated to $109.8 million in Q2 2026 per TNDM's latest filing, from $110.4 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $125.2 million in Q4 2024 and bottomed at $84.8 million in Q1 2022.
• Historically, Cost of Revenue has averaged $106.0 million across 5 years, with a median of $107.0 million in 2022.
• The sharpest annual moves came in 2022 and 2026: Cost of Revenue rose 25.19% in 2022, then fell 4.81% in 2026.
• Over 5 years, Cost of Revenue stood at $105.0 million in 2022, then decreased by 1.41% to $103.5 million in 2023, then advanced by 20.96% to $125.2 million in 2024, then fell by 1.81% to $122.9 million in 2025, then decreased by 10.69% to $109.8 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $109.8 million, $110.4 million, and $122.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.